YOLFTbeta
Nightingale Health Oyj B

Nightingale Health Oyj B

HEALTH · HE · Healthcare / Health Information Services

1.90EUR+0.02 (+1.06%)

Price History

Full chart

Market Stats

Previous Close1.88
Open1.89
Day Range1.88 – 1.94
52-Week Range0.786 – 2.66
Volume74.95K
Market Cap77.87M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.31
Dividend Yield0.00%
Beta0.33
50-Day Avg0.9148
200-Day Avg1.22

About

Nightingale Health Oyj, a health technology company, offers advanced health check that detects disease risks in Finland, the United Kingdom, rest of Europe, the United States, and internationally. The company's Health Check that detects the risks associated with various common chronic diseases from a single blood sample; and Remote Health Check where health check done remotely. It also offers blood analysis, self collection kits, urine analysis, and biomarkers services. It provides its services to research programs, universities, and healthcare providers. The company has a collaboration with Personalised Health Clinics to incorporate the company's metabolomic blood testing into Personalised Health Clinics' personalized, clinician-led healthcare services. Nightingale Health Oyj was incorporated in 2002 and is headquartered in Helsinki, Finland.

Company Details

  • SectorHealthcare
  • IndustryHealth Information Services
  • CEOMr. Teemu Suna
  • Employees101
  • HeadquartersMannerheimintie 164a, Helsinki, Finland, 00300, Finland
  • Websitehttps://nightingalehealth.com

Leadership

  • Mr. Teemu SunaFounder, Interim CFO, CEO & Director · b. 1982
  • Mr. Antti KangasFounder, CTO & Director · b. 1984
  • Ms. Satu SaksmanCo-Founder & Chief Commercial Officer of APAC · b. 1976
  • Mr. Peter Wurtz Ph.D.Founder & Scientific Director
  • Mr. Pasi Soininen Ph.D.Founder & Laboratory Director
  • Ms. Janna RantaCOO and Chief Commercial Officer of Research & Healthcare · b. 1985
  • Ms. Satu Sirén-LähdeahoGeneral Counsel
  • Ms. Minja SalmioChief Commercial Officer of EMEA Region · b. 1987
  • Ms. Salla Ruosaari Ph.D.Chief Research & Development Officer · b. 1976
  • Dr. Charles AlessiChief Clinical Officer

Financials

Income Statement

Currency: EUR2020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue1.78M2.31M2.31M4.18M4.36M4.69M5.50M
Growth (%)-+29.43%+0.35%+80.80%+4.21%+7.69%+17.24%
Cost of Revenue13.61K291.00K958.00K590.00K1.45M1.14M2.66M
Gross Profit1.77M2.01M1.35M3.59M2.91M3.56M2.84M
Gross Margin99.24%87.38%58.58%85.89%66.75%75.75%51.67%
Operating Expense5.11M11.77M14.99M22.12M21.50M22.97M21.65M
Operating Income-3.34M-9.75M-13.63M-18.52M-18.59M-19.42M-18.80M
Operating Margin-187.68%-423.17%-589.45%-442.95%-426.62%-413.74%-341.78%
EBITDA-3.12M-2.55M-11.18M-11.38M-8.42M-8.82M-11.17M
EBITDA Margin-174.94%-110.68%-483.44%-272.19%-193.18%-188.05%-203.05%
Net Income-3.73M-9.72M-16.09M-18.08M-17.46M-18.46M-18.47M
Net Income Margin-209.51%-421.91%-695.68%-432.40%-400.71%-393.39%-335.73%
R&D92.97K347.00K1.23M596.00K213.00K--
R&D as % of Total Revenue5.22%15.05%52.96%14.25%4.89%--
Interest Expense386.32K125.00K23.00K34.00K31.00K37.00K378.00K
Interest Expense % of Total Revenue21.69%5.42%0.99%0.81%0.71%0.79%6.87%

Balance Sheet

Currency: EUR2020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets23.79M138.99M124.05M106.79M90.84M74.51M58.06M
Total Liabilities15.06M15.95M12.61M9.44M7.96M8.35M9.32M
Total Equity8.73M123.04M111.44M97.36M82.88M66.17M48.74M
Cash905.21K113.81M95.28M80.64M43.65M41.29M36.80M
Net Debt4.93M------

Cash Flow

Currency: EUR2020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-3.17M-1.87M-7.47M-7.33M-8.41M-10.11M-10.88M
Investing Cash Flow-7.80M-6.61M-8.32M-4.41M-25.54M9.46M-
Financing Cash Flow5.40M121.38M-2.86M-2.58M-2.83M-1.58M-
Capital Expenditure8.19M895.00K1.37M833.00K4.59M4.15M2.21M
Free Cash Flow-11.35M-5.58M-15.09M-11.74M-13.00M-14.26M-13.10M
FCF to OCF358.54%298.18%201.86%160.23%154.57%141.10%120.35%

Key Statistics & Ratios

Market Cap77.87M
Enterprise Value23.19M
Trailing P/E0.00
Forward P/E0.00
Price / Sales14.15
Price / Book1.15
EPS-0.31
Book Value0.807
Revenue (TTM)5.50M
Gross Profit (TTM)2.84M
EBITDA-13.99M
Profit Margin0.00%
Operating Margin-324.64%
Return on Equity-32.15%
Return on Assets-17.73%
Shares Outstanding40.65M
Shares Float29.25M
Beta0.33
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%